Fujifilm begins U.S. study of its drug candidate FF-10832 in combination with Keytruda
seekingalpha.com
finance
2022-05-31 15:03:43

winhorse/iStock Unreleased via Getty Images Japan's Fujifilm (OTCPK:FUJIY) on Tuesday said it had begun a U.S. phase 2a study of its drug candidate FF-10832 in combination with Merck's (MRK) Keytruda for the treatment of various cancers. The mid-stage trial's primary aim is to establish the safety and tolerability of FF-10832 in combination with Keytruda in patients with advanced solid tumors. The trial's primary aim is to also evaluate the combination's primary efficacy in non-small cell lung cancer and urothelial cancer patients who have progressed after standard therapy, including immune checkpoint inhibitor therapy.
